title: Generation of Reactive Oxygen Species in Peripheral Blood Lymphocytes of Patients with Prostate Cancer.
abstract: The study revealed a two-fold elevation of ROS production in peripheral blood lymphocytes of the patients with prostate cancer (from 0.48±0.04 to 0.93±0.12 rel. units) together with significant variability of individual values. Hormone therapy had no effect on the mean and individual ROS levels. In contrast, organometallic cytostatics cisplatin and morfozol 2-fold increased ROS generation in lymphocytes of patients with prostate cancer above the enhanced level of this parameter determined by tumor growth.
authors.affiliation: N. M. Emanuel Institute of Biochemical Physics, Russian Academy of Sciences, Moscow, Russia. annagrekhova1@gmail.com.
authors.forename: A K
authors.initials: AK
authors.lastname: Grekhova
authors.affiliation: N. M. Emanuel Institute of Biochemical Physics, Russian Academy of Sciences, Moscow, Russia.
authors.forename: L B
authors.initials: LB
authors.lastname: Gorbacheva
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002945:Cisplatin / Q000627:therapeutic use; D006801:Humans; D008214:Lymphocytes / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D010084:Oxidation-Reduction; D010165:Palladium / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000473:pathology*; D017382:Reactive Oxygen Species / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D017382:Reactive Oxygen Species; D010165:Palladium; D002945:Cisplatin
keywords: cisplatin; lymphocytes; morfozol; prostate cancer; reactive oxygen species